Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BD inks definitive TriPath purchase pact

This article was originally published in The Gray Sheet

Executive Summary

Becton Dickinson's purchase of TriPath Imaging under a definitive $350 mil. agreement, announced Sept. 8, is in line with the terms of BD's initial mid-August purchase offer (1"The Gray Sheet" Aug. 21, 2006, p. 3). TriPath's SurePath cervical cancer screening technology and molecular oncology diagnostics will dovetail with BD's flow cytometry systems for the detection of lymphoma and leukemia to advance BD's position in cancer diagnostics, BD says. Combination of the complementary businesses builds on the firms' 2001 collaboration to develop molecular diagnostics for various forms of cancer. BD expects the deal to close by year-end, pending TriPath shareholder approval and antitrust clearance...

You may also be interested in...



BD’s TriPath Imaging Buyout Would Integrate Cancer Diagnostics Partner

Becton Dickinson will gain TriPath Imaging's SurePath liquid-based Pap test and fledgling molecular oncology diagnostics business should its $350 mil. acquisition offer be accepted

Merz Consumer Care Optimistic About Future As German Lockdown Continues

Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure. 

Towa Plans 10 Launches In December 2020

After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well. 

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel